Domestic and Overseas Expansion of the Antifungal-Agent Business
First written in FY2016. 10 of 28 entries say "Advanced", first in FY2017. Latest entry: FY2026.
4 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「In the Pharmaceuticals business, sales of luliconazole, a topical antifungal agent, remained firm in Japan, including for onychomycosis.」
The company reconfirmed that domestic sales of luliconazole for onychomycosis remained steady. - FY2026-H1AdvancedAnnual report
「In the pharmaceutical business, sales of the topical antifungal agent luliconazole for toenail fungus and other domestic indications increased as inventory in the distribution channel was reduced and shipments to distributors accelerated, among other factors.」
The resolution of distribution inventory and faster shipments to distributors increased domestic sales of luliconazole, resulting in specific progress in the antifungal business. - FY2025Sluggish sales due to excess inventory held by distributorsAnnual report
「In the pharmaceutical business, sales of the topical antifungal agent luliconazole for toenail fungus remained sluggish due to the impact of excess inventory held by distributors.」
Regarding the domestic and overseas expansion of the antifungal business, the company reported sluggish sales of luliconazole against the backdrop of excess distributor inventory for onychomycosis products. - FY2025-H1RestatedAnnual report
「In the pharmaceutical business, sales of the topical antifungal agent luliconazole for toenail fungus remained sluggish.」
Regarding the domestic and overseas expansion of the antifungal business, the company reconfirmed sluggish sales of luliconazole for onychomycosis. - FY2024-Q3Sluggish sales due to the end of sales in ChinaAnnual report
「In the pharmaceutical business, sales were sluggish following the discontinuation of luliconazole sales in China.」
Regarding the domestic and overseas expansion of the antifungal business, the company explained that revenue from luliconazole struggled to grow following the end of sales in China. - FY2024-Q2RestatedAnnual report
「In the pharmaceutical business, sales of the topical antifungal agent luliconazole remained sluggish due to lower overseas demand, among other factors.」
The company reconfirmed sluggish sales of the topical antifungal luliconazole against the backdrop of weaker overseas demand. - FY2024-Q1Sluggish sales due to lower overseas demandAnnual report
「In the pharmaceutical business, sales of the topical antifungal agent luliconazole remained sluggish due to lower overseas demand, among other factors.」
Regarding the domestic and overseas expansion of the antifungal business, the company explained that luliconazole sales struggled to grow against the backdrop of weaker overseas demand. - FY2023RestatedAnnual report
「In the pharmaceutical business, sales of topical antifungal agents remained firm.」
The company reconfirmed that antifungal sales remained steady. - FY2023-Q3AdvancedAnnual report
「In the pharmaceutical business, sales of topical antifungal agents remained firm.」
Sales of topical antifungals changed from sluggish through the previous period to steady in the current quarter, indicating an improvement in sales trends in the antifungal business. - FY2023-Q1RestatedAnnual report
「Meanwhile, in the pharmaceutical business, sales of the topical antifungal agent luliconazole remained sluggish for both athlete's foot and toenail fungus treatments.」
The company reconfirmed that luliconazole sales in both the tinea pedis and onychomycosis segments remained sluggish. - FY2022Deterioration in sales trendsAnnual report
「Meanwhile, in the pharmaceutical business, sales of the topical antifungal agent luliconazole remained sluggish as the number of outpatients at medical institutions declined due to the spread of COVID-19, among other factors.」
Regarding the domestic and overseas expansion of the antifungal business, sluggish sales of luliconazole against the backdrop of fewer outpatient visits have continued. - FY2022-Q3Deterioration in sales trendsAnnual report
「Meanwhile, in the pharmaceutical business, sales of the topical antifungal luliconazole struggled to grow, partly because the number of outpatient visits to medical institutions declined as the COVID-19 pandemic spread.」
Regarding luliconazole, the description changed from previously reported strong sales and revenue growth to sluggish sales against the backdrop of fewer outpatient visits. - FY2022-Q2Deterioration in sales trendsAnnual report
「Meanwhile, in the pharmaceutical business, sales of the topical antifungal luliconazole struggled to grow.」
Regarding luliconazole, the description changed from previously reported revenue growth and strong sales to sluggish sales. - FY2022-Q1Sluggish sales in the onychomycosis segmentAnnual report
「Meanwhile, in the pharmaceutical business, sales of the topical antifungal luliconazole in the onychomycosis segment struggled to grow.」
The company reported sluggish sales of the topical antifungal luliconazole in the onychomycosis segment. - FY2021AdvancedAnnual report
「Meanwhile, in the pharmaceutical business, sales of the topical antifungal agents luliconazole and lanoconazole in the athlete's foot segment increased.」
Revenue from 2 antifungal agents in the tinea pedis segment increased, indicating progress in expanding the domestic and overseas business. - FY2021-Q3RestatedAnnual report
「In the pharmaceutical business, sales of the topical antifungal agent luliconazole increased.」
The company reconfirmed the increase in luliconazole sales. - FY2021-Q2AdvancedAnnual report
「In the pharmaceutical business, revenue from the topical antifungals lanoconazole and luliconazole increased.」
The company reported sales progress in the antifungal business, driven by higher revenue from lanoconazole and luliconazole. - FY2021-Q1AdvancedAnnual report
「In the pharmaceutical business, sales of the topical antifungal agent luliconazole in the toenail fungus segment increased.」
Revenue from luliconazole in the onychomycosis segment increased, indicating specific progress in the expansion of the antifungal business. - FY2020-Q3AdvancedAnnual report
「In the pharmaceutical business, sales of the topical antifungal agents lanoconazole and luliconazole increased.」
The growth in revenue from 2 topical antifungal agents indicates specific sales progress in the antifungal pharmaceutical business. - FY2020-Q1RestatedAnnual report
「In addition, in the pharmaceutical business, sales of the topical antifungal luliconazole in the onychomycosis segment remained strong.」
The company reconfirmed strong sales of luliconazole in the onychomycosis segment. - FY2019-Q4RestatedAnnual report
「In the pharmaceutical business, sales of the topical antifungal agent luliconazole in the toenail fungus segment remained strong.」
The company reconfirmed strong sales of luliconazole in the onychomycosis segment. - FY2019-Q3AdvancedAnnual report
「In the pharmaceutical business, revenue from the topical antifungal luliconazole in the onychomycosis segment increased.」
Revenue from luliconazole in the onychomycosis segment increased, indicating specific sales progress in the antifungal business. - FY2018AdvancedAnnual report
「In the pharmaceutical business, sales of the topical antifungal agent luliconazole in the toenail fungus segment remained strong.」
The company reported specific progress in the antifungal business, driven by strong sales of luliconazole in the onychomycosis segment. - FY2019-Q1RestatedAnnual report
「In the pharmaceutical business, sales of the topical antifungal luliconazole in the onychomycosis segment remained steady.」
The company reconfirmed steady sales of luliconazole in the onychomycosis segment. - FY2018-Q4Sales trends diverged by segmentAnnual report
「In the pharmaceutical business, sales of the topical antifungal luliconazole in the onychomycosis segment remained steady. However, sales in the tinea pedis segment struggled to grow, and revenue fell below the same period of the previous year.」
While luliconazole performed steadily in the onychomycosis segment, sales in the tinea pedis segment struggled to grow, and revenue from the antifungal business fell below the same period of the previous year. - FY2018-Q3AdvancedAnnual report
「In the pharmaceutical business, sales exceeded the same period of the previous year, supported by steady sales of the topical antifungal lanoconazole.」
The company reported steady sales of the topical antifungal lanoconazole and higher revenue in the pharmaceutical business. - FY2017AdvancedAnnual report
「In the pharmaceutical business, sales of the topical antifungal luliconazole in the tinea pedis segment remained strong.」
The company reported specific progress in the antifungal business, with strong sales of luliconazole in the tinea pedis segment. - FY2016First statedAnnual report
「In addition, the company is working to strengthen its sales of pesticides for landscaping and non-crop areas, as well as its termite-control chemicals business, and plans to expand its domestic and overseas antifungal pharmaceutical business.」
The company has identified domestic and overseas business expansion for antifungal agents as a key initiative.